Genenta Science S.p.A. (GNTA) NASDAQ
2.20
+0.55(+33.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Genenta Science S.p.A.
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 15, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Pierluigi Paracchi | Co-Founder, Chairman, Chief Executive Officer & GM | 0 | 1973 |
| Bernard Rudolph Gentner | CO-Founder & Scientific Advisory Board Member | 0 | 1975 |
| Francesco Galimi | Chief Medical Officer, Head of Development & Director | 0 | 1968 |
| Luigi Naldini | Co-Founder & Chairman of Scientific Advisory Board | 0 | 1959 |
| Stefania Mazzoleni | Director of Program Development | 0 | 1982 |
| Gianfranco De Nigris | Vice President Corporate Development | 0 | N/A |
| Barbara Regonini | Director of Finance | 0 | 1973 |
| Richard Slansky | Chief Financial Officer | 0 | 1958 |
Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
